Questions for Endeavor
This article was originally published in The Gray Sheet
European regulatory authorities reviewing a CE mark application for Medtronic's Endeavor drug-eluting stent are requesting further information on the drug compound (ABT-578) supplied by Abbott. Medtronic expects Endeavor to earn European go-ahead after resolution of these "few remaining regulatory questions," the firm says in a May 31 release, acknowledging that regulators have not estimated a timeline for final review. Medtronic previously forecast a CE mark for Endeavor in mid-2005 (1"The Gray Sheet" April 15, 2005, p. 5)...
You may also be interested in...
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.